Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ) just unveiled an update.
Jiangsu Recbio Technology Co., Ltd. has established a Nomination Committee to enhance its governance structure by regulating the appointment of directors and senior management. This move aims to rationalize the board’s composition and improve the company’s operational efficiency, potentially impacting its industry positioning positively.
The most recent analyst rating on (HK:2179) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the biotechnology industry. The company focuses on the development and commercialization of innovative vaccines and biopharmaceutical products.
Average Trading Volume: 39,478
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.69B
See more insights into 2179 stock on TipRanks’ Stock Analysis page.